Navigation Links
Crescendo Biologics Announces First 'Triple Knockout' Mouse
Date:9/29/2010

Crescendo Biologics Announces First 'Triple Knockout' Mouse -- CAMBRIDGE, England, September 29, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, New Products & Services, Clinical Trials & Medical Discoveries Click to view news release full screen  

Crescendo Biologics Announces First 'Triple Knockout' Mouse

 

CAMBRIDGE, England, September 29, 2010 /PRNewswire/ --

- Mice Lacking Endogenous Antibody Polypeptides Offer Powerful New Tool for Antibody Fragment Development

Crescendo Biologics Limited (Crescendo) today announces it has established a colony of engineered mice completely devoid of endogenous antibody polypeptides. The proprietary 'triple knockout' mice are believed to be unique and have the immunoglobulin heavy chain (IgH), kappa light chain and lambda light chain loci all functionally silenced by large-scale genomic deletion.

This is a significant advance over previous knockout mice which retain intact lambda light chain. While lambda light chain accounts for at most 10% of the light chains in mouse antibodies, Crescendo believes that knockout of all light chain expression is critical for the efficient generation of human heavy chain antibodies in transgenic mice. The new knockout mouse thus offers an enhanced background for the generation of new antibody therapeutics and is a key step in the establishment of Crescendo's world-leading VH antibody fragment platform. VH fragments are the smallest fragments that retain antibody binding, and have many desirable properties as potential therapeutics.

In a parallel development, Crescendo has also demonstrated the potential of its first generation yeast artificial chromosome (YAC) with the successful expression of human antibodies. Working with Professor Lluis Montoliu at the Centro Nacional de Biotecnologia (a centre belonging to the Spanish National Research Council, CSIC) in Madrid, transgenic mice have been generated by oocyte microinjection with a first YAC comprising several human V genes, all human D and J genes and a C region engineered for expression in the absence of light chains. This YAC has been shown to rearrange and express human antibodies in wild type mice.

"Today's announcement marks an important milestone in the development of our highly innovative antibody fragment technology," said Mike Romanos, CSO of Crescendo Biologics. "We have successfully delivered what we believe to be a unique asset in our triple knockout mice, and have also made significant steps in the generation of YACs which direct the production of human heavy chain antibodies. When combined, and with further developments in our YAC technology, we believe we will have the strongest platform for the generation of new VH fragment therapeutics and can harness the great benefits they will bring as therapeutics."

The Crescendo approach is aimed at bringing together two highly desirable characteristics of antibody platforms - human origin and in vivo maturation - to allow rapid creation of high affinity fragments. The company intends to progress at least one VH-based product to the clinic.

Crescendo is now working to generate mice that combine its newly developed YAC and the triple knockout mouse, in order to generate a first generation Crescendo mouse platform. In addition, Crescendo is generating additional YAC transgenics to progress towards the best in class mouse.

About Crescendo Biologics Ltd

Crescendo Biologics will apply highly innovative antibody fragment technologies to the development of new targeted therapeutics. The Crescendo transgenic mouse platform under development has the potential to rapidly and predictably generate high-affinity human heavy chain antibodies that readily yield VH fragments that have no requirement for humanisation. This is combined with a powerful in vitro ribosome display technology which offers significant advantages over existing approaches in antibody optimisation. VH fragments provide great flexibility as a starting point for the development of new targeted therapeutics combining the specificity and binding affinity of antibodies with certain desirable characteristics of small molecules.

Crescendo's technologies were invented by scientists at the Babraham Institute, Cambridge (UK). The Company has raised GBP4.5 million in seed funding from leading life sciences investors, Sofinnova Partners with Aitua, Avlar BioVentures and the Rainbow Seed Fund also participating. http://www.crescendobiologics.com

Contacts Mike Romanos/Amanda Bettison Crescendo Biologics Tel: +44-(0)1223-497140 Email: mromanos/abettison@crescendobiologics.com Chris Gardner Citigate Dewe Rogerson Tel: +44-(0)207-638-9571 Email: chris.gardner@citigatedr.co.uk
'/>"/>

SOURCE Crescendo Biologics Ltd
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Crescendo Biologics Raises GBP4.5 million in Seed-Funding Led by Sofinnova Partners
2. Immune Biosimilars Will Erode $10.8 Billion in Immune Biologics Brand Sales in 2019 Across the U.S., EU5 and Japan
3. Edimer Pharmaceuticals and CMC Biologics Announce Agreement to Manufacture EDI200 Recombinant Protein
4. Reportlinker Adds Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies
5. Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential
6. Bone Biologics Announces a Major US Patent Issuance For Its Recombinant Protein Process For the Formation of Cartilage
7. Bone Biologics Announces Another Round of Equity and Debt Investment by Musculoskeletal Transplant Foundation and the Addition of Board Member, Mark Spilker
8. Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL(R) (agalsidase alfa) With the U.S. Food and Drug Administration (FDA)
9. In 2012, Stelara and Briakinumab Will Capture 22 Percent of the Biologics Share in the Moderate to Severe Psoriasis Drug Market
10. Dendreon Completes Submission of Biologics License Application for PROVENGE
11. ImaginAb, Inc. and BZL Biologics, LLC Conclude Licensing Agreement for Imaging Rights to huJ591/Prostate-Specific Membrane Antigen (PSMA)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... Research and Markets has announced the ... Markets" report to their offering. ... The study scope includes ... RNA interference, synthetic biology tools and genome editing tools); synthetic ... These technologies and products are analyzed to determine present and ...
(Date:3/28/2017)... , ... March 28, 2017 , ... Franz Inc ... product, AllegroGraph , has been named a ‘Champion’ by Bloor Research in its ... highest ranked product in its class, and, thanks to Gruff, it was rated as ...
(Date:3/28/2017)... and WASHINGTON , March 28, ... provider, GENEWIZ, will launch single-cell sequencing during the American Association ... E. Washington Convention Center in Washington, D.C. ... to perform differential gene expression of thousands of cells ... Experts on-hand at AACR ...
(Date:3/28/2017)... -- Biostage, Inc. (Nasdaq: BSTG), ("Biostage" or ... to treat cancers and other life-threatening conditions of the ... McGorry, CEO of Biostage, will present on the ... MassBio 2017 Annual Meeting on Thursday, March ... The 3D Printing and BioEngineering panel will ...
Breaking Biology Technology:
(Date:3/20/2017)... , March 20, 2017 At this year,s CeBIT ... -based biometrics manufacturer DERMALOG. The Chancellor came to the DERMALOG stand together ... is this year,s CeBIT partner country. At the largest German biometrics company ... use: fingerprint, face and iris recognition as well as DERMALOG´s multi-biometrics system.   ... ...
(Date:3/9/2017)... MOUNTAIN VIEW, Calif. , March 9, ... Simple," and 23andMe , the leading personal genetics ... choices.  Zipongo can now provide customers with personalized nutrition ... goals and biometrics, but also genetic markers impacting how ... Zipongo,s personalized food decision support platform uses biometrics ...
(Date:3/2/2017)... 2017 Summary This report provides ... KGaA and its partnering interests and activities since 2010. ... Description The Partnering Deals and Alliance since 2010 report ... one of the world,s leading life sciences companies. ... to ensure inclusion of the most up to date ...
Breaking Biology News(10 mins):